Clinical Oncology - Issue Supplementum 3/2019
Editorial
Review
6
Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment
O. Bílek, M. Holánek, J. Berkovcová, O. Horký, T. Kazda, H. Čoupková, S. Špelda, L. Kristková, M. Zvaríková, J. Podhorec, S. Bořilová, L. Bohovicová, L. Zdražilová Dubská
13
CRISPR-Cas9 as a Tool in Cancer Therapy
P. Zatloukalová, R. Krejčíř, D. Valík, B. Vojtěšek
19
Synthetic Lethality – Its Current Application and Potential in Oncological Treatment
L. Bortlíková, P. Müller, B. Vojtěšek, V. Rak, M. Svoboda
25
Progress in the Utilisation of Organometallic Compounds in the Development of Cancer Drugs
H. Skoupilová, R. Hrstka
34
39
Glycoproteins in the Sera of Oncological Patients
L. Hernychová, L. Uhrík, R. Nenutil, M. V. Novotný
46
Glycosylation as an Important Regulator of Antibody Function
L. Uhrík, L. Hernychová, B. Vojtěšek
56
Protein Ubiquitination Research in Oncology
J. Faktor, M. Pjechová, L. Hernychová, B. Vojtěšek
65
Long Non-Coding RNAs – Current Methods of Detection and Clinical Applications
L. Moráňová, M. Bartošík
72
Oncogenic Viral Protein Interactions with p53 Family Proteins
V. Brychtová, V. Hrabal, B. Vojtěšek
78
Cooperation of Genomic, Transcriptomics and Proteomic Methods in the Detection of Mutated Proteins
F. Zavadil Kokáš, J. Faktor, B. Vojtěšek
Clinical Oncology
2019 Issue Supplementum 3
Most read in this issue
- Protein Ubiquitination Research in Oncology
- CRISPR-Cas9 as a Tool in Cancer Therapy
- Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment
- Glycosylation as an Important Regulator of Antibody Function